Kolumne, ORE

Original-Research: MLP SE - from NuWays AG Classification of NuWays AG to MLP SE Company Name: MLP SE ISIN: DE0006569908 Reason for the research: Update Recommendation: Buy from: 11.07.2024 Target price: EUR 11.50 Last rating change: Analyst: Henry Wendisch Another performance fee quarter ahead; chg.

11.07.2024 - 09:02:32

Original-Research: MLP SE (von NuWays AG): Buy


Original-Research: MLP SE - from NuWays AG

Classification of NuWays AG to MLP SE

Company Name: MLP SE
ISIN: DE0006569908

Reason for the research: Update
Recommendation: Buy
from: 11.07.2024
Target price: EUR 11.50
Last rating change: 
Analyst: Henry Wendisch

Another performance fee quarter ahead; chg. est.
 
Topic: With the end of Q2, two major public funds of MLP's asset manager
FERI have surpassed their respective cut-off dates, above their old HWM and
benchmarks. As a result, we expect the collection of another EUR 4.2m
performance fees from public funds in Q2, in detail:
 
Optoflex as main performance fee driver: On June 28th 2024, FERI's second
largest public fund (EUR 1.3bn AuM) has again surpassed its old HWM from 31st
March 2024 while achieving a 1pp outperformance over its hurdle-rate (Euro
short-term rate, EURSTR). As the Optoflex records performance fees on a
quarterly basis (vs. yearly at most other funds), we consequently expect a
EUR 3.9m performance fee contribution from the Optoflex in Q2.
 
Euro Equity Flex with a small contribution: This EUR 247m large fund records
performance fees only on a yearly basis with its cutoff date on June 30th.
On this day, the fund recorded a 14.9% performance above its old HWM from
June 30th 2023, while its benchmark (EURO STOXX 50 Net Return) recorded a
14.0% performance in the same period. Consequently, 15% of the 0.9pp
outperformance is eligible for performance fees which we estimate to be EUR
0.3m for Q2 (see p. 2).
Potential upside from private equity carries: historically, FERI has
collected c. EUR 1-2m performance fees from its alternative assets in the
second quarter (Q2'22: EUR 1.1m; Q2'23: EUR 2m). These are discrete events and
can not be observed from the outside. Therefore, it remains a blackbox for
us, whether private equity carries will be recorded or not in Q2'24e,
posing as a potential upside of EUR 1-2m (see p. 2).
 
AuM composition dominated by FERI: as of Q1'24, FERI makes up c. 81% of
MLP's EUR 59.3bn AuM base. Here, 1) public funds make up c. EUR 3.6bn, while
the largest parts are 2) alternative assets of c.EUR 17.5bn (i.e. hedgefunds,
private equity, infrastructure and real estate) and 3) c. EUR 28bn of 'other
assets' which are undisclosed but should be made up of liquid
assets/securities for individual investment strategies and white label
solutions for institutional clients, in our view (see p. 2).
 
Against this backdrop, we now incorporate EUR 4.2m performance fees in our
model (prev. EUR 2m). As our new EBIT estimate of EUR 90m (old: EUR 88m) is
substantially above the EUR 75-85m EBIT guidance, a guidance upgrade with Q2
results seems likely. Therefore, we reiterate our BUY recommendation with
an unchanged PT of EUR 11.50, based on FCFY'24e and SOTP.

You can download the research here:
http://www.more-ir.de/d/30189.pdf
For additional information visit our website
www.nuways-ag.com/research.

Contact for questions
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++

-------------------transmitted by EQS Group AG.-------------------


The issuer is solely responsible for the content of this research.
The result of this research does not constitute investment advice
or an invitation to conclude certain stock exchange transactions.

@ dpa.de

Weitere Meldungen

Original-Research: ParTec AG (von First Berlin Equity Research GmbH): Buy Original-Research: ParTec AG - from First Berlin Equity Research GmbH 22.11.2024 / 11:20 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 11:21) weiterlesen...

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 11:06) weiterlesen...

Original-Research: ad pepper media International N.V. (von First Berlin Equit... Original-Research: ad pepper media International N.V. - from First Berlin Equity Research GmbH 22.11.2024 / 10:45 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 10:46) weiterlesen...

Original-Research: NFON AG (von NuWays AG): Buy Original-Research: NFON AG - from NuWays AG 22.11.2024 / 09:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 09:06) weiterlesen...

Original-Research: Nabaltec AG (von NuWays AG): Buy Original-Research: Nabaltec AG - from NuWays AG 22.11.2024 / 09:01 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 09:02) weiterlesen...

Original-Research: mVISE AG (von NuWays AG): Buy Original-Research: mVISE AG - from NuWays AG 22.11.2024 / 09:01 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. (Boerse, 22.11.2024 - 09:01) weiterlesen...